Reporter Cell Line Engineering for Therapeutic Antibody Evaluation in Animal Health

Summary

Biologics for companion animals are advancing, but the reporter cell lines needed to characterise them are often not commercially available, with little supporting literature. FairJourney Bio engineered two custom reporter cell lines, for a dual-chain receptor and a GPCR, to evaluate blocking antibodies in animal health. Both reached IND-ready status with validated IC50 readouts, in under 3.5 months from vector design to clone delivery.

Problem

Reporter cell lines are essential for antibody screening, potency, and lot release, but for companion-animal targets the tools and literature are scarce. GPCRs are especially hard: complex signalling, unstable receptor expression, and low dynamic range work against a sensitive readout.

Approach

FairJourney Bio combined transposase technology with custom dual-vector design and optimized protocols. Stable pools were single-cell sorted by FACS using tagged ligands, then screened by luciferase assay. Top clones were selected on fold induction, with EC70 set for each ligand.

Outcome

Two reporter cell lines for two complex targets reached validated, IND-ready clones in under 3.5 months from vector design. Lead antibodies showed full blocking, with IC50 near 0.24 nM (dual-chain) and 6.9 nM (GPCR), and the assays were transferred to the client.

Key Results